-transparent.png){kind=logo}
2'-Deoxycoformycin (2'-dCF), a tight-binding inhibitor of adenosine deaminase, was administered to 26 pediatric patients with acute lymphoblastic leukemia in a Phase I study. Doses ranged from 0.25 to 1.0 mg/kg given i.v. for 3 consecutive days. Common toxicity included nausea, vomiting, diarrhea, hepatocellular enzyme elevations, and conjunctivitis. Lymphopenia occurred in all patients. The most serious adverse effects were acute tubular necrosis and central nervous system toxicity, which appeared to be dose related. In addition, two patients given the 0.75-mg/kg dose developed severe hepatic toxicity, although this could not be ascribed definitively to 2'-dCF. Antitumor activity was observed in eight patients, two of whom experienced a complete remission. Inhibition of lymphoblast adenosine deaminase activity was noted in the majority of cases and was observed at all doses. Antileukemic activity occurred at doses of 2'-dCF which were not associated with limiting toxicities. These results suggest that 2'-dCF is active against acute lymphoblastic leukemia and that a starting dose of 0.5 mg/kg/day be utilized in Phase II studies.
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
January 1979,
Advances in experimental medicine and biology,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
January 1993,
Transplantation,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
January 1979,
Cancer treatment reports,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
December 2016,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
June 1992,
Japanese journal of clinical oncology,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
January 2016,
Leukemia & lymphoma,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
March 2022,
Cancer medicine,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
July 2015,
Haematologica,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
July 2020,
Blood advances,
D G Poplack, and
S E Sallan, and
G Rivera, and
J Holcenberg, and
S B Murphy, and
J Blatt, and
J M Lipton, and
P Venner, and
D L Glaubiger, and
R Ungerleider, and
D Johns
April 2020,
Cancer science,
